Literature DB >> 21110146

A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.

Koichiro Suemori, Hiroshi Fujiwara, Seiichiro Watanabe, Taichi Azuma, Masaki Yasukawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21110146     DOI： 10.1007/s12185-010-0729-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  Hypersensitivity pneumonitis related to imatinib mesylate.

Authors:  A Bergeron; E Bergot; G Vilela; L Ades; A Devergie; H Espérou; G Socié; F Calvo; E Gluckman; P Ribaud; Ph Rousselot; A Tazi
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

2.  Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration.

Authors:  T Yokoyama; K Miyazawa; E Kurakawa; A Nagate; T Shimamoto; K Iwaya; S Akata; M Aoshima; H Serizawa; K Ohyashiki
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

3.  Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.

Authors:  Manuel F Rosado; Elio Donna; Yeon S Ahn
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

4.  Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.

Authors:  Jay Rajda; Pradyumna D Phatak
Journal:  Am J Hematol       Date:  2005-05       Impact factor: 10.047

5.  Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.

Authors:  K Ohnishi; F Sakai; S Kudoh; R Ohno
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

6.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

7.  Variable expression of platelet-derived growth factor family proteins in acute lung injury.

Authors:  J Walsh; M Absher; J Kelley
Journal:  Am J Respir Cell Mol Biol       Date:  1993-12       Impact factor: 6.914

8.  Acute lung injury. Pathogenesis of intraalveolar fibrosis.

Authors:  L S Snyder; M I Hertz; M S Peterson; K R Harmon; W A Marinelli; C A Henke; J R Greenheck; B Chen; P B Bitterman
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

Review 10.  Pulmonary complications of novel antineoplastic agents for solid tumors.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Chest       Date:  2008-02       Impact factor: 9.410
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.